Efficacy and Tolerability of Advanced Glycation End-Products Inhibitor in Osteoarthritis

Garg, Shabnam; Syngle, Ashit; Vohra, Kanchan

doi:10.1097/ajp.0b013e318272ebec

Cited by 25 publications

(24 citation statements)

References 46 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with these observations, intervention studies with a low-AGE diet have shown a decrease mainly of inflammatory parameters [42]. AGEs are also involved in structural changes of articular cartilage; they may therefore represent an effective therapeutic target in OA [26,29]. For these reasons, we aimed at investigating whether the modification of AGE levels through therapeutic fasting can be a mechanism explaining the pain relief and functional improvement in patients with OA.…”

Section: Discussionmentioning

confidence: 99%

“…Activation of RAGE by AGEs leads to increased production of metalloproteinases by chondrocytes and synoviocytes, and further degradation of cartilage with release of cartilage fragments [28]. Based on these observations, it is conceivable that the development of drugs inhibiting the formation of AGEs may reduce OA pain scores and inflammatory markers [29]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

AGE-RAGE Interaction Does Not Explain the Clinical Improvements after Therapeutic Fasting in Osteoarthritis

et al. 2017

View full text Add to dashboard Cite

Background: Therapeutic fasting improves joint pain in patients with osteoarthritis (OA), but the underlying mechanisms are unknown. Interactions of advanced glycation end products (AGEs) and their receptors (RAGE) play a role in OA pathogenesis. This study aimed to investigate whether the benefits of fasting in OA can be explained by changes in AGEs or RAGE. Patients and Methods: 37 patients with OA underwent fasting for 8 days. Serum levels of an AGE (N-ε-(carboxymethyl)-lysine; CML) and the soluble RAGE (sRAGE) as well as clinical outcome parameters such pain characteristics (measured by visual analogue scale; VAS), joint function (determined by the Western Ontario and McMaster Universities Arthritis Index; WOMAC), and quality of life (via the 36-Item Short-Form Health Survey (SF-36) questionnaire) were assessed. The variables were measured at baseline, the end of fasting, and at follow-up at 4 weeks. Results: The CML levels did not significantly change from baseline to the end of intervention (Δ = -25.6 ± 92.2 ng/ml; p = 0.10). In contrast, the sRAGE levels (Δ = -182.7 ± 171.4 ng/ml; p < 0.0001) and the sRAGE/CML ratio (Δ = -0.4 ± 0.6; p < 0.001) significantly decreased, but they returned to baseline levels 4 weeks after the end of fasting. The scores for pain, WOMAC, and the physical subscale of the SF-36 significantly improved during fasting. There was no correlation between the clinical outcomes and changes in serum levels of CML, sRAGE, or the sRAGE/CML ratio. Conclusions: Fasting resulted in a significant but non-sustained reduction of sRAGE levels and the sRAGE/CML ratio in OA, while the CML levels did not change. Improvement in clinical endpoints of OA does not correlate with changes in CML or sRAGE.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

AGE-RAGE Interaction Does Not Explain the Clinical Improvements after Therapeutic Fasting in Osteoarthritis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The natural vitamin B6 analog, pyridoxamine, is a drug that may potentially be effective in diabetic nephropathy and retinopathy (42)(43)(44)(45)(46)(47)(48)(49)(50)(51). Metformin is also a putative candidate (52)(53)(54).…”

Section: Discussionmentioning

confidence: 99%

Contribution of methylglyoxal to delayed healing of bone injury in diabetes

Aikawa

Matsubara

Ugaji

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract.Patients with diabetes are vulnerable to delayed bone fracture healing or pseudoarthrosis. Chronic sustained hyperglycemia, reactive intermediate derivatives of glucose metabolism, such as methylglyoxal (MGO), and advanced glycation end-products (AGEs) are implicated in diabetic complications. In the present study, it was examined whether MGO is able to cause disturbed bone healing in diabetes. Diabetes was induced in male mice by injection of streptozotocin (50 mg/kg) for 5 days. A bone defect (1.0-mm diameter) was created in the left distal femur, and bone repair was assessed from an examination of computed tomography scans. ST2 cells were exposed to MGO (0-400 µM) to investigate osteoblastic differentiation, cell viability, and damage. Consequently, blood glucose and hemoglobin A1c levels in diabetic mice were determined to be 493±14.1 mg/dl and 8.0±0.05%, respectively. Compared with non-diabetic control mice, diabetic mice exhibited markedly delayed bone healing, with increased levels of the MGO-derived AGEs, N ε -(carboxymethyl)-lysine and N δ -(5-hydro-5-methyl-4-imida zolone-2-yl)-ornithine, in the sera and femurs. MGO inhibited the osteoblastic differentiation of ST2 cells in a dose-dependent manner, and markedly decreased cell proliferation through cytotoxicity. In conclusion, MGO has been demonstrated to cause impaired osteoblastic differentiation and delayed bone repair in diabetes. Therefore, detoxification of MGO may be a potentially useful strategy against bone problems in patients with diabetes.

show abstract

“…In addition, Bvits had anti-inflammatory and anti-itching action, the latter in post-herpetic neuralgia patients and have also improved functionality. When those vitamins were associated to conventional acute or chronic pain management, they have decreased time for analgesic and antiinflammatory drugs consumption, thus contributing to less deleterious adverse effects in some individuals 1,7,[10][11][12][13][14][15][16][17][18][19][20] . The review of publications on Bvits for neuropathic pain, a total of 6 studies, point to beneficial effects, but with different doses and administration routes.…”

Section: Discussionmentioning

confidence: 99%

“…So, vitamin B12 as analgesic adjuvant could be an alternative for acute back, cervical and hip pain when there are higher risks for the use of anti-inflammatory drugs. In other nociceptive pains such as knee OA and pain after limb fracture, Bvits have also shown analgesic effects 1,19,20 , both alone and in association with anti-inflammatory drugs, in addition to benefits for inflammation (decreased C-reactive protein serum levels in monotherapy) and functional capacity 19,20 . Although observing a role of Bvits as analgesics in nociceptive pain, it was not possible to establish most effective doses, as it also was the case for neuropathic pain, because formulations and doses of studied trials were quite different.…”

Section: Discussionmentioning

confidence: 99%

B complex vitamins for analgesic therapy

Gazoni¹,

Malezan²,

Santos³

2016

Revista Dor

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES:The B complex vitamins have been used as single therapy or combined to other drugs, such as anti-inflammatory drugs, in different clinical situations, such as degenerative spinal diseases, rheumatologic diseases, polyneuropathies and in different postoperative situations. This study aimed at identifying in the scientific literature most recent evidences of the use of B complex vitamins as analgesic therapy and at describing clinical situations where their analgesic action could be observed. CONTENTS: A search was carried out in Pubmed, Medline, LILACS, Cochrane Library and Scielo databases, contemplating the last 10 years and titles in Portuguese, Spanish and English. Keywords were: "pain", "B complex vitamins", "management", "vitamin B1", "vitamin B6", "vitamin B12", "thiamine", "pyridoxine" and "cyanocobalamin". Among 40 studies found, we have selected just musculoskeletal and neuropathic pain trials with humans, and where B complex vitamins were used as analgesic agents. From these, 13 studies were selected for meeting inclusion criteria. In all of them, B complex vitamins played roles in analgesia, even when in single therapy. B complex vitamins had also anti-inflammatory and anti-pruritus action, in addition to improving functionality. CONCLUSION: Existing studies, although scarce and heterogeneous, have shown that B complex vitamins have analgesic effect. They are considered safe and have low cost and have shown to be a good option as adjuvant analgesic therapy. Keywords: B complex vitamins, Management, Pain. B complex vitamins for analgesic therapy O uso de vitaminas do complexo B em terapêutica analgésica RESUMO JUSTIFICATIVA E OBJETIVOS:As vitaminas do complexo B têm sido utilizadas em monoterapia ou combinada a outros fár-macos, como os anti-inflamatórios, em diversas situações clinicas, como por exemplo, nas doenças degenerativas da coluna, doenças reumatológicas, polineuropatias e nos pós-operatórios diversos. O objetivo deste estudo foi identificar na literatura científica as evidências mais recentes do uso de vitaminas do complexo B como terapia analgésica e descrever as situações clínicas em que se pode verificar a sua ação analgésica. CONTEÚDO: Realizada a revisão bibliográfica na base de dados do Pubmed, Medline, LILACS, Biblioteca Cochrane e Scielo, contemplando os últimos 10 anos, títulos em português, espanhol e inglês. Os descritores utilizados foram: "Dor", "vitaminas do complexo B", "tratamento", "vitamina B1", "vitamina B6", "vitamina B12", "tiamina", "piridoxina" e "cianocobalamina". Dentre os 40 estudos encontrados selecionaram-se apenas os trials em dor musculoesquelética e neuropática com seres humanos, e em que as vitaminas do complexo B configuraram-se como agentes analgésicos. Foram selecionados então 13 estudos que satisfizeram esses critérios de inclusão. Em todos eles as vitaminas do complexo B desempenharam papéis na analgesia, inclusive quando em monoterapia. As vitaminas do complexo B também apresentaram ação anti-inflamatória, anti-prurigi...

show abstract

Efficacy and Tolerability of Advanced Glycation End-Products Inhibitor in Osteoarthritis

Abstract: This study shows the efficacy of an AGE inhibitor on decreasing pain and inflammation, and increasing daily activity and mobility in OA patients.

Cited by 25 publications

References 46 publications

AGE-RAGE Interaction Does Not Explain the Clinical Improvements after Therapeutic Fasting in Osteoarthritis

AGE-RAGE Interaction Does Not Explain the Clinical Improvements after Therapeutic Fasting in Osteoarthritis

Contribution of methylglyoxal to delayed healing of bone injury in diabetes

B complex vitamins for analgesic therapy

Contact Info

Product

Resources

About